Below are the transcripts from the Q2 earnings call. This transcript is brought to you by Benzinga APIs. For real-time access ...

Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically ...

Analysts estimate that Altimmune will report an earnings per share (EPS) of $-0.32. Anticipation surrounds Altimmune's ...

Today, several major companies are expected to report earnings: Inovio Pharmaceuticals (INO), Altimmune (ALT), Sea (SE), ...

Reports Q2 revenue $5,000 vs $5,000 last year. “Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive ...

We read with interest the Correspondence by Zhiqi Yao and colleagues1 published in The Lancet Diabetes & Endocrinology, which ...